In order to treat depression (anxiety)-like behaviors, in which FAAH blockade was described as a successful therapeutic option in mouse models [390], it recently occurred that participants in a phase 1 study of a compound known as BIA 10-2474, a presumed selective FAAH inhibitor, were hospitalized with severe neurological symptoms, presumably due to off-target proteins [391]. The gene discussed is FAAH; the disease is Anxiety.